Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2009 1
2010 1
2011 1
2012 1
2013 2
2014 2
2015 1
2016 1
2017 3
2018 4
2019 4
2020 11
2021 11
2022 10
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
Robbins CJ, Fernandez AI, Han G, Wong S, Harigopal M, Podoll M, Singh K, Ly A, Kuba MG, Wen H, Sanders MA, Brock J, Wei S, Fadare O, Hanley K, Jorns J, Snir OL, Yoon E, Rabe K, Soong TR, Reisenbichler ES, Rimm DL. Robbins CJ, et al. Among authors: reisenbichler es. Mod Pathol. 2023 Jan;36(1):100032. doi: 10.1016/j.modpat.2022.100032. Mod Pathol. 2023. PMID: 36788069 Free PMC article.
Cryptococcal chest wall mass and rib osteomyelitis associated with the use of fingolimod: A case report and literature review.
Carpenter K, Etemady-Deylamy A, Costello V, Khasawneh M, Chamberland R, Tian K, Donlin M, Moreira-Walsh B, Reisenbichler E, Abate G. Carpenter K, et al. Among authors: reisenbichler e. Front Med (Lausanne). 2022 Sep 7;9:942751. doi: 10.3389/fmed.2022.942751. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36160166 Free PMC article.
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer.
Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. Rozenblit M, et al. Among authors: reisenbichler e. Breast Cancer Res Treat. 2022 Nov;196(1):221-227. doi: 10.1007/s10549-022-06712-2. Epub 2022 Aug 26. Breast Cancer Res Treat. 2022. PMID: 36028784
Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
Sahoo S, Krings G, Chen YY, Carter JM, Chen B, Guo H, Hibshoosh H, Reisenbichler E, Fan F, Wei S, Khazai L, Balassanian R, Klein ME, Shad S, Venters SJ, Borowsky AD, Symmans WF, Ocal IT. Sahoo S, et al. Among authors: reisenbichler e. Arch Pathol Lab Med. 2022 May 1;147(5):591-603. doi: 10.5858/arpa.2022-0021-EP. Arch Pathol Lab Med. 2022. PMID: 35976643 Free article.
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Foldi J, et al. Among authors: reisenbichler e. Clin Cancer Res. 2022 Sep 1;28(17):3720-3728. doi: 10.1158/1078-0432.CCR-22-0862. Clin Cancer Res. 2022. PMID: 35903931 Free PMC article. Clinical Trial.
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer.
Marczyk M, Qing T, O'Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. Marczyk M, et al. Among authors: reisenbichler e. NPJ Breast Cancer. 2022 Jul 22;8(1):88. doi: 10.1038/s41523-022-00449-3. NPJ Breast Cancer. 2022. PMID: 35869114 Free PMC article.
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Blenman KRM, et al. Among authors: reisenbichler e. Clin Cancer Res. 2022 Jun 13;28(12):2587-2597. doi: 10.1158/1078-0432.CCR-21-3215. Clin Cancer Res. 2022. PMID: 35377948 Free PMC article. Clinical Trial.
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Foldi J, et al. Among authors: reisenbichler e. NPJ Breast Cancer. 2022 Feb 3;8(1):17. doi: 10.1038/s41523-022-00392-3. NPJ Breast Cancer. 2022. PMID: 35115541 Free PMC article. No abstract available.
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.
Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. Fernandez AI, et al. Among authors: reisenbichler e. JAMA Oncol. 2022 Apr 1;8(4):1-4. doi: 10.1001/jamaoncol.2021.7239. JAMA Oncol. 2022. PMID: 35113160 Free PMC article.
46 results